[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360664-105":59,"doc-detail-360664-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","antibody-drug-conjugates-in-solid-tumor-oncology-and-the-frontier-of-precision-immunosuppression-a-mechanistic-translational-and-clinical-review","Antibody-Drug Conjugates in Solid Tumor Oncology and the Frontier of Precision Immunosuppression - A Mechanistic, Translational, and Clinical Review","","Antibody-drug conjugates (ADCs) have evolved into a defining therapeutic class for solid tumor oncology. Clinical advances, exemplified by DESTINY-Breast03 and EV-302, highlight benefits driven by the linker-payload axis and extracellular release, spanning multiple cancer types. Mechanistic analysis focuses on vascular limitation, binding-site concentration at the perivascular margin, and antigen mosaicism undermining internalization-dependent killing. Translational and clinical sections address coordinated resistance and the movement toward earlier-line, curative-intent use, including lessons from autoimmune delivery attempts with ABBV-154.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antibody-drug-conjugates-in-solid-tumor-oncology-and-the-frontier-of-precision-immunosuppression-a-mechanistic-translational-and-clinical-review/360664/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antibody-drug-conjugates-in-solid-tumor-oncology-and-the-frontier-of-precision-immunosuppression-a-mechanistic-translational-and-clinical-review/360664.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the linker-payload axis explain about ADC efficacy in solid tumors?","Question",{"text":112,"@type":113},"It links cleavable linker chemistry and payload type to observed advantages, emphasizing how structural features drive delivery and functional bystander activity rather than antibody engineering alone.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which tumor biology barriers are used to organize the mechanistic analysis?",{"text":117,"@type":113},"The review organizes mechanisms around vascular limitation, the binding-site barrier at the perivascular margin, and antigen mosaicism that disrupts internalization-dependent killing.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review describe resistance and where does it arise across systems?",{"text":121,"@type":113},"Resistance is framed as a coordinated failure across antigen modulation, trafficking, efflux, apoptotic execution, and lysosomal processing.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360664,1790198640,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Review  \nAntibody-Drug Conjugates in Solid Tumor Oncology and the Frontier of Precision Immunosuppression: A Mechanistic, Translational, and Clinical Review  \nIbraheem Masoud 1,†, Nada Saed Homod Al Shaer 1,†, Ahmad Masoud 1, Ahmad Al Jandali 1, Abdulrahman Aldahash 1, Abdullah Jabri 1, Mohamed Alsharif 1, Fareeha Arshad 1, Itika Arora 1, Mohammed Imran Khan 2 and Ahmed Yaqinuddin 1, *  \nAcademic Editor: Anna Lisa Giuliani  \nReceived: 15 May 2026  \nRevised: 2 June 2026  \nAccepted: 4 June 2026  \nPublished: 9 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia; [imasoud@alfaisal.edu](imasoud@alfaisal.edu) (I.M.); [nalshaer@alfaisal.edu](nalshaer@alfaisal.edu) (N.S.H.A.S.); [amasoud@alfaisal.edu](amasoud@alfaisal.edu) (A.M.); [aaljandali@alfaisal.edu](aaljandali@alfaisal.edu) (A.A.J.); [amaldahash@alfaisal.edu](amaldahash@alfaisal.edu) (A.A.); [ajabri@alfaisal.edu](ajabri@alfaisal.edu) (A.J.); [moalsharif@alfaisal.edu](moalsharif@alfaisal.edu) (M.A.); [farshad@alfaisal.edu](farshad@alfaisal.edu) (F.A.); [iarora@alfaisal.edu](iarora@alfaisal.edu) (I.A.)  \n2 Research Center, King Faisal Specialist Hospital and Research Center, Jeddah 21499, Saudi Arabia; [mikhan@kfshrc.edu.sa](mikhan@kfshrc.edu.sa)  \n* Correspondence: [ayaqinuddin@alfaisal.edu](ayaqinuddin@alfaisal.edu)[ ](ayaqinuddin@alfaisal.edu)† These authors contributed equally to this work.  \nAbstract  \nAntibody-drug conjugates (ADCs) have transitioned from clinically marginal agents into a defining therapeutic class for solid tumor oncology. In DESTINY-Breast03, trastuzumab deruxtecan achieved a four-fold progression-free survival advantage over trastuzumabemtansine, attributable not to antibody engineering but to the linker-payload axis: a cleavable peptide linker and a topoisomerase I payload with bystander activity. Sacituzumab govitecan extends the same logic to Trop-2-positive disease via extracellular payload release, and the framework now spans breast, urothelial, gynecologic, lung, gastric, and colorectal cancers, with enfortumab vedotin plus pembrolizumab displacing platinum chemotherapy as first-line therapy for urothelial cancer in EV-302 (median overall survival 31.5 versus 16.1 months) . This review synthesizes ADC biology along three analytical axes. The mechanistic axis links each linker-payload-DAR configuration to a specific tumor-biology barrier: vascular limitation, which delivers approximately 0.1% of the administered dose to tumor tissue; the binding-site barrier, which concentrates exposure at the perivascular margin; and antigen mosaicism, which defeats internalization-dependent killing. The translational axis examines resistance as a coordinated failure across antigen modulation, trafficking, efflux, apoptotic execution, and lysosomal processing. The clinical axis traces the platform’s migration toward earlier-line and curative-intent settings. We close by examining whether the ADC delivery architecture translates to precision immunosuppression in autoimmune disease, where the glucocorticoid receptor modulator ADC ABBV-154 met placebo-controlled efficacy endpoints in rheumatoid arthritis but was discontinued because its benefit-risk profile did not differentiate it from existing biologic therapies.  \nKeywords: antibody-drug conjugate; trastuzumab deruxtecan; enfortumab vedotin; tumor heterogeneity; bystander effect; linker-payload axis; solid tumor; precision immunosuppression  \n1. Introduction  \nThe conceptual foundation of antibody-drug conjugates originates in Paul Ehrlich’s early 1900s “magic bullet” hypothesis. Yet nearly a century of iterative engineering separated this vision from its first clinical realization, reflecting not a failure of principle but a persistent mismatch between ADC chemistry and the biologi","cbCaihLg5Lw8IfJI","https://ap.wps.com/l/cbCaihLg5Lw8IfJI","pdf",9365000,43,"English","# Abstract\n## ADC clinical evolution and key trial outcomes\n## Mechanistic axes: delivery barriers and payload architecture\n## Translational axis: coordinated resistance mechanisms\n## Clinical axis: earlier-line/curative-intent movement and autoimmune exploration\n# Introduction\n## From Ehrlich’s “magic bullet” to ADC engineering iterations\n## Linker stability, toxicity, and early-generation limitations\n## FDA approvals, reapprovals, and benefit-risk refinements\n## Second- and third-generation design improvements and bystander effects","[{\"question\":\"What does the linker-payload axis explain about ADC efficacy in solid tumors?\",\"answer\":\"It links cleavable linker chemistry and payload type to observed advantages, emphasizing how structural features drive delivery and functional bystander activity rather than antibody engineering alone.\"},{\"question\":\"Which tumor biology barriers are used to organize the mechanistic analysis?\",\"answer\":\"The review organizes mechanisms around vascular limitation, the binding-site barrier at the perivascular margin, and antigen mosaicism that disrupts internalization-dependent killing.\"},{\"question\":\"How does the review describe resistance and where does it arise across systems?\",\"answer\":\"Resistance is framed as a coordinated failure across antigen modulation, trafficking, efflux, apoptotic execution, and lysosomal processing.\"}]","Antibody-Drug Conjugates in Solid Tumor Oncology and the Frontier of Precision Immunosuppression - A Mechanistic, Translational, and Clinical Review | PDF",1790140985,108,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d717c88d5b3a9a5cbd8371ef1758480a.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f057d503dd38a0df4b6a0e610d9d961.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1d624ccb1c2d0a6b5009e60863eb965.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdbd395981470c60140d752b4c72b6c6.webp",980,1385,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5caf87ef1a7fd9a1c8b4e0d052679687.webp",979,1384]